CN104666267B - 一种阿昔洛韦药物组合物 - Google Patents
一种阿昔洛韦药物组合物 Download PDFInfo
- Publication number
- CN104666267B CN104666267B CN201510040993.XA CN201510040993A CN104666267B CN 104666267 B CN104666267 B CN 104666267B CN 201510040993 A CN201510040993 A CN 201510040993A CN 104666267 B CN104666267 B CN 104666267B
- Authority
- CN
- China
- Prior art keywords
- acv
- release
- carbohydrate
- lubricant
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 9
- 239000000314 lubricant Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000003792 electrolyte Substances 0.000 claims abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 239000011122 softwood Substances 0.000 claims description 9
- 239000001856 Ethyl cellulose Substances 0.000 claims description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 7
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 7
- 229920001249 ethyl cellulose Polymers 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 235000020985 whole grains Nutrition 0.000 claims description 7
- 241000416162 Astragalus gummifer Species 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 229920001615 Tragacanth Polymers 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000196 tragacanth Substances 0.000 claims description 6
- 235000010487 tragacanth Nutrition 0.000 claims description 6
- 229940116362 tragacanth Drugs 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 235000013312 flour Nutrition 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 238000005868 electrolysis reaction Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 abstract description 9
- 229960004150 aciclovir Drugs 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 5
- 238000013268 sustained release Methods 0.000 abstract description 4
- 239000012730 sustained-release form Substances 0.000 abstract description 4
- 239000007939 sustained release tablet Substances 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 239000003405 delayed action preparation Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- YKBGVTZYEHREMT-UHFFFAOYSA-N 2-amino-9-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- BYEIJZFKOAXBBV-ATZCPNFKSA-N N-[(5S)-5-amino-5-carboxypentanoyl]-L-cysteinyl-D-valine Chemical compound CC(C)[C@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)CCC[C@H](N)C(O)=O BYEIJZFKOAXBBV-ATZCPNFKSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940107931 zovirax Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510040993.XA CN104666267B (zh) | 2015-03-27 | 2015-03-27 | 一种阿昔洛韦药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510040993.XA CN104666267B (zh) | 2015-03-27 | 2015-03-27 | 一种阿昔洛韦药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104666267A CN104666267A (zh) | 2015-06-03 |
CN104666267B true CN104666267B (zh) | 2017-08-08 |
Family
ID=53302214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510040993.XA Active CN104666267B (zh) | 2015-03-27 | 2015-03-27 | 一种阿昔洛韦药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104666267B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101212957A (zh) * | 2005-06-29 | 2008-07-02 | 万能药生物有限公司 | 药物缓释组合物及其制备方法 |
CN101502521A (zh) * | 2008-09-04 | 2009-08-12 | 山东淄博新达制药有限公司 | 阿昔洛韦缓释制剂组合物及其制备方法 |
CN101647786A (zh) * | 2008-08-15 | 2010-02-17 | 北京科信必成医药科技发展有限公司 | 阿昔洛韦缓释片及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200903854B (en) * | 2008-06-19 | 2011-02-23 | Univ Of The Witwatesrand Johannesburg | A gastroretentive pharmaceutical dosage form |
-
2015
- 2015-03-27 CN CN201510040993.XA patent/CN104666267B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101212957A (zh) * | 2005-06-29 | 2008-07-02 | 万能药生物有限公司 | 药物缓释组合物及其制备方法 |
CN101647786A (zh) * | 2008-08-15 | 2010-02-17 | 北京科信必成医药科技发展有限公司 | 阿昔洛韦缓释片及其制备方法 |
CN101502521A (zh) * | 2008-09-04 | 2009-08-12 | 山东淄博新达制药有限公司 | 阿昔洛韦缓释制剂组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
阿昔洛韦缓释片的制备及体外释药的研究;吕竹芬等;《广东药学院学报》;20021231;第18卷(第4期);第263-256页 * |
阿昔洛韦缓释片的工艺研究;吴宁萍等;《中国现代应用药学杂志》;20040831;第21卷(第4期);第276-278页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104666267A (zh) | 2015-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104039319B (zh) | 用于治疗hcv的组合物和方法 | |
CN109350611B (zh) | 包覆魔芋葡甘露聚糖的nmn纳米微球及其制备工艺与应用 | |
CN103070864B (zh) | 一种瑞格列奈和盐酸二甲双胍药物组合物及其制备方法 | |
CN106619662B (zh) | 一种含有富马酸替诺福韦二吡呋酯的口服干混悬剂及其制备方法 | |
WO2012133658A1 (ja) | サプリメントを内包する蓋体とサプリメント分散媒を充填したボトルからなるボトル入り飲料 | |
CN106860414A (zh) | 一种用于抗hiv的复方制剂及其制备方法与应用 | |
CN104363896A (zh) | 恩替卡韦的药物组合物及制造方法 | |
CN101103960A (zh) | 一种含有消旋卡多曲的干混悬剂及其制备方法 | |
CN104666267B (zh) | 一种阿昔洛韦药物组合物 | |
CN104666274A (zh) | 一种缬沙坦胶囊的制备方法 | |
JP2009091362A6 (ja) | 高含量ファムシクロビル錠剤 | |
JP2009091362A (ja) | 高含量ファムシクロビル錠剤 | |
CN100471497C (zh) | 盐酸纳洛酮鼻粉剂 | |
CN106860464A (zh) | 用于联合抗病毒治疗的药物组合物及应用 | |
CN105769779A (zh) | 一种阿昔洛韦分散片及其制备方法 | |
CN104382873B (zh) | 一种吗替麦考酚酯分散片 | |
CN101647786B (zh) | 阿昔洛韦缓释片及其制备方法 | |
CN100435804C (zh) | 司他夫定口服速释制剂及制备方法 | |
CN105343026B (zh) | 草酸艾司西酞普兰泡腾片配方与制备工艺 | |
EP1180033A2 (en) | Lamivudine containing pharmaceutical formulation | |
JP2015107951A (ja) | 顆粒剤 | |
CN100435797C (zh) | 茚地那韦口服速释制剂及制备方法 | |
CN114392239B (zh) | 一种拉米夫定、齐多夫定和依非韦伦的复方片及其制备方法 | |
CN102784116A (zh) | 一种高溶出度非诺贝特分散片及其制备方法 | |
CN102988320B (zh) | 一种卡培他滨分散片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Acyclovir pharmaceutical composition Effective date of registration: 20210730 Granted publication date: 20170808 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211014 Granted publication date: 20170808 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021430000029 |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No.8 Kangpu Avenue, high tech Industrial Park, Hanshou County, Changde City, Hunan Province, 415900 Patentee after: KAMP PHARMACEUTICALS Co.,Ltd. Address before: 12 / F, building B, Lugu information port, 658 Lugu Avenue, high tech Zone, Changsha City, Hunan Province, 410205 Patentee before: KAMP PHARMACEUTICALS Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Acyclovir pharmaceutical composition Effective date of registration: 20211028 Granted publication date: 20170808 Pledgee: Hunan Hanshou Rural Commercial Bank Co.,Ltd. Pledgor: KAMP PHARMACEUTICALS Co.,Ltd. Registration number: Y2021980011259 |